Vico Therapeutics, a pioneering clinical-stage genetic medicines company, has successfully closed its Series B funding round with a total investment of €65.8 million ($70.7 million). This financing round, led by Seroba and Kurma Partners, marks a significant milestone in Vico’s journey towards developing transformative therapies for severe neurological diseases.
Vico Therapeutics specializes in antisense oligonucleotide (ASO) RNA-modulating therapies aimed at diseases such as spinocerebellar ataxia types 3 and 1 (SCA3 and SCA1) and Huntington’s disease, all of which currently lack disease-modifying treatments. The company’s lead program, VO659, is currently in a Phase 1/2a clinical study, focusing on assessing its safety and efficacy in patients suffering from these debilitating neurodegenerative conditions.
Seroba, known for its strategic investments in cutting-edge biotech and medtech innovations, expressed confidence in Vico’s potential to redefine treatment paradigms in neurology. Catello Somma, Partner at Seroba, emphasized the impact of this funding in advancing Vico’s clinical programs and enhancing patient outcomes. Similarly, Kurma Partners highlighted their longstanding partnership with Vico, underscoring their commitment to supporting the company’s growth and innovation in genetic therapies.
Daniel Parera and Jean-Francois Rivassou, Partners at Kurma, praised Vico’s progression from early-stage development to clinical trials, affirming their continued support through the Kurma Growth Opportunities Fund. This collaboration reflects a shared vision of leveraging scientific expertise and strategic investment to address critical unmet needs in healthcare.
Vico Therapeutics, founded in 2019, leverages its proprietary platform, VICOMER, to design precise RNA modulators tailored for specific neurological disorders. This approach includes mechanisms such as translation inhibition and splicing modulation, aimed at optimizing target engagement and safety profiles across different disease states.
Micah Mackison, CEO of Vico Therapeutics, expressed gratitude towards investors and highlighted the strategic importance of this funding in accelerating clinical development. With ongoing efforts to expand their pipeline and enhance therapeutic options for patients, Vico remains dedicated to advancing innovative solutions in genetic medicine.
Our View:
Vico Therapeutics stands at the forefront of genetic medicine innovation, harnessing cutting-edge RNA-modulating technologies to address complex neurological diseases. Their commitment to rigorous clinical development and strategic partnerships underscores their potential to deliver significant advancements in patient care.
Potential Ahead:
The substantial backing from investors like Seroba and Kurma Partners positions Vico Therapeutics for continued success in advancing their therapeutic programs. With promising early-stage results and a robust pipeline, Vico is poised to make substantial contributions to the treatment landscape of severe neurological disorders, offering hope to patients and families affected worldwide.
